Holen Sie sich die Stockscreener-App
264.58
0.09%
-0.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$264.75
Offen:
$263.09
24-Stunden-Volumen:
652.36K
Relative Volume:
0.40
Marktkapitalisierung:
$51.48B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
20.30
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
+1.31%
1M Leistung:
-15.32%
6M Leistung:
-27.66%
1J Leistung:
-9.21%
1-Tages-Spanne:
$261.90
$267.39
1-Wochen-Bereich:
$255.07
$268.87
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
264.60 | 51.51B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
761.30 | 90.72B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
200.46 | 46.66B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
73.62 | 8.34B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.51 | 1.37B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Cencora stock (US15135B1017): transformation story after name change and solid earnings - AD HOC NEWS
Cencora stock (US15135B1017): Earnings miss and legal probe weigh on shares - AD HOC NEWS
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora hits 52-week low after guidance cut - MSN
Cencora stock (US15135B1017): Q2 miss, legal probe and what matters now for investors - AD HOC NEWS
Cencora stock (US15135B1017): dividend track record and legal investigation in focus - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Investors to Connect - The National Law Review
Investors can join fraud probe against Cencora after Q2 miss and revenue drop claims. - Pluang
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating - Insider Monkey
Cencora stock (US15135B1017): revenue miss, guidance tweak and share price pressure in focus - AD HOC NEWS
Cencora Inc. stock underperforms Wednesday when compared to competitors - MSN
Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative? - simplywall.st
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? - MSN
Is It Time To Revisit Cencora (COR) After The Recent Share Price Slump? - simplywall.st
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR - The Joplin Globe
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora stock (US15135B1017): pharma distributor reshapes portfolio after latest earnings - AD HOC NEWS
Wells Fargo Maintains Overweight Rating on Cencora (COR) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Stockholders to Connect - The National Law Review
Cencora, Inc. Common Stock (NY: COR - FinancialContent
Cencora faces securities fraud probe after missing revenue targets and stock plunge. - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc.COR - PR Newswire
Cencora, Inc.: - marketscreener.com
Cencora Inc. stock (US15135B1017): dividend date and legal probe in focus for investors - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? - TradingView
ETFs Investing in Cencora, Inc. Stocks - TradingView
Are Wall Street Analysts Bullish on Cencora Stock? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cencora, Inc. (COR) Investors to Inquire about Securities Investigation - The National Law Review
Cencora Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Cencora stock (US15135B1017): Q2 2026 earnings show 7% revenue growth - AD HOC NEWS
Cencora stock (US15135B1017): Q2 earnings miss, analyst downgrades weigh on shares - AD HOC NEWS
Why is Cencora stock trading lower on Wednesday? - MSN
Why Cencora (COR) is a Top Growth Stock for the Long-Term - Yahoo Finance
Cencora stock (US15135B1017): Drops 17% after Q2 earnings miss - AD HOC NEWS
Houston County receives state funding for industrial access work tied to Cencora expansion - WTVY
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced - The National Law Review
TD Cowen reiterates Cencora stock Buy rating on generics thesis - Investing.com UK
TD Cowen reiterates Cencora stock Buy rating on generics thesis By Investing.com - Investing.com South Africa
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - ChartMill
Research Alert: CFRA Maintains Buy Rating On Shares Of Cencora - Moomoo
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
FinancialContentCencora, Inc. (COR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Kepler Cheuvreux Suisse SA Has $9.77 Million Position in Cencora, Inc. $COR - MarketBeat
Cencora (NYSE:COR) Could Be A Buy For Its Upcoming Dividend - simplywall.st
Cencora, Inc. (COR) Stock Analysis: A 36.74% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): Healthcare distribution leader posts solid Q2 results - AD HOC NEWS
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):